OmniAb, Inc.
Vidhyashankar (Vidhya) Ramamurthy has a strong background in business development and strategy, with experience in various leadership roles. Vidhyashankar (Vidhya) is currently serving as the Director of Business Development at OmniAb, Inc. since March 2023. Prior to this, they were the Director of Business Initiatives, Strategy & Operations at The Janssen Pharmaceutical Companies of Johnson & Johnson from October 2021 to November 2022. Before that, they worked at Janssen Inc. as the Associate Director of Alliance/Contract Management, Business Operations from November 2018 to October 2021. Vidhya also held positions at Syngene International Limited, where they served as the Senior Director of Business Development from June 2018 to November 2018, and as an Associate Director from December 2011 to May 2018. Vidhyashankar (Vidhya) started their career at Bristol-Myers Squibb as a Sr. Research Investigator, where they worked from June 1999 to December 2011.
Vidhyashankar (Vidhya) Ramamurthy's education history begins in 1991 when they enrolled at the University of Madras. Vidhyashankar (Vidhya) completed their Bachelor of Science degree in Chemistry in 1994. Vidhyashankar (Vidhya) then went on to pursue their Master of Science degree in Biotechnology at the Indian Institute of Technology, Bombay, from 1994 to 1996. After completing their master's degree, Vidhya attended the University of Delaware from 1996 to 1999, earning a Master of Science degree in Chemistry/Biochemistry. Finally, they pursued an MBA in Marketing at Rutgers University from 2004 to 2009.
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.